Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2003

View Archived Issues

Antimetastatic effects of a CXCR4 antagonist evaluated in vitro and in vivo in mice

Inhibitex and Texas A&M researchers claim SdrG-targeted antibodies as bacterial vaccines

New CDK inhibitors recently identified at Schering AG

Walter Reed Army Institute scientists prepare and test a novel antimalarial agent

Novel antibacterial carbapenems presented by Wyeth Lederle Japan researchers

Pfizer designs new alpha1L-adrenoceptor antagonists for BPH therapy

GSK team develops new calcitonin agonists with potential in bone disorders

Phase IIb trial of ATL-962 for obesity meets primary endpoint

Positive preliminary findings emerge from phase IIb trial of renzapride for mixed-symptom IBS

Phase III IND filed for interferon alfa lozenges for oral warts in HIV patients

SBIR grant supports GPCR efforts at Novasite

Third-quarter progress at Genzyme

ISTA updates pipeline progress

Quarterly highlights at Karo Bio

Positive data reported on AGT-MI for angiogenic therapy

Sunesis acquires exclusive rights to SPC-595

Orally active PDE5 inhibitor shows potential for use in pulmonary hypertension

Preclinical efficacy of the cannabinoid CB1 receptor antagonist SR-14176A in improving memory

Development and marketing agreement for Ventavis signed for U.S.

Potential role suggested for arginase inhibitors in the treatment of overactive bladder

A novel target described for the therapy of chronic cystitis

Endothelin receptors suggested as potential targets for overactive bladder

Stampidine as a potential nonspermicidal anti-HIV microbicide

Benefits reported for a menotropin/follitropin alfa combination in IVF

Effects of trimegestone/conjugated estrogens in postmenopausal women

Beneficial effects on cholesterol and adiposity for EM-652 in ovariectomized animals